VolitionRX (VNRX) AI Stock Analysis

• Market Cap: $76.43M
• Dividend Yield: N/A
• Average Volume (3M): 270.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: 64.15%
• EPS Growth: 41.65%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.06
• Shares Outstanding: 103,982,020
• 10 Day Avg. Volume: 174,582
• 30 Day Avg. Volume: 270,697
• PEG Ratio: -0.22
• Price to Book (P/B): -3.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 13.82
• Enterprise Value/Gross Profit: 50.76
• Enterprise Value/Ebitda: -0.62
• 1Y Price Target: $2.75
• Price Target Upside: 271.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 54 Neutral
• Price Target: $1.00 ▲(35.14%Upside)

VolitionRX's overall stock score is driven primarily by its significant financial challenges, which heavily weigh down the score. However, positive technical trends and an optimistic earnings call with strategic advancements provide some counterbalance. The lackluster valuation further impacts the score, highlighting the company's high-risk profile.

Positive Factors

Innovation

VolitionRx demonstrated quantification of nucleosomes in whole venous blood in minutes using a lateral flow device, showcasing early detection of immune disruptions.

Partnerships

The anticipated announcement of a partnership in the human health space is seen as the most important catalyst, potentially providing non-dilutive capital and validating the business strategy.

Revenue Growth

Revenue grew 44% in 1Q25, with licensing deals expected to boost financial performance.

Negative Factors

Licensing Challenges

Failure to secure license agreements for diagnostic products could hinder market traction and financial growth.

Market Risks

Risks include failure in clinical development, failure to secure license agreements, and going concern risk.

Market Skepticism

The market is discounting the likelihood of success in human health, despite favorable clinical data and ongoing discussions with potential partners.

VolitionRX Business Overview & Revenue Model

Company Description

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

How the Company Makes Money

VolitionRX generates revenue primarily through the sale of its diagnostic tests, leveraging its Nucleosomics technology to offer innovative solutions for early disease detection. The company's revenue model involves selling these diagnostic products to healthcare providers, laboratories, and potentially through partnerships with larger corporations in the medical diagnostics field. Revenue is also supplemented by collaborations with research institutions and licensing agreements, where VolitionRX partners with other entities to co-develop or distribute their technology, thereby expanding their market reach and sharing in the resulting profits.

VolitionRX Financial Statement Overview

Summary

VolitionRX is facing significant financial difficulties, evidenced by consistent net losses, negative equity, and reliance on external financing. Despite modest revenue growth, its financial position remains precarious across all financial statements.

Income Statement

VolitionRX's income statement reveals a challenging financial position with consistent net losses. The gross profit margin remains positive at 100% due to low revenue, while net profit margins are significantly negative due to large operating expenses. The revenue growth shows a positive trajectory, increasing by approximately 6.1% in the TTM, yet the company struggles with substantial negative EBIT and EBITDA margins, indicating high operational costs relative to revenue.

Balance Sheet

The balance sheet presents a precarious financial situation with negative stockholders' equity, suggesting the company is heavily leveraged. The debt-to-equity ratio cannot be calculated due to negative equity, but this signifies high financial risk. Total liabilities significantly exceed total assets, indicating potential solvency issues. The low equity ratio further supports the company's weak financial position.

Cash Flow

Cash flow analysis shows VolitionRX faces substantial negative free cash flow, although free cash flow did improve slightly from the previous year. The operating cash flow remains negative, indicating insufficient cash generation from operations to cover expenses. Financing activities have been a primary source of cash, suggesting dependency on external funding to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.23M	775.30K	306.39K	90.03K	13.43K
Gross Profit	1.23M	775.30K	-882.03K	90.03K	13.43K
EBITDA	-25.62M	-34.04M	-29.24M	-25.69M	-19.23M
Net Income	-26.97M	-35.32M	-30.27M	-26.97M	-20.48M
Balance Sheet
Total Assets	9.40M	27.95M	18.30M	27.49M	26.15M
Cash, Cash Equivalents and Short-Term Investments	3.26M	20.73M	10.87M	20.58M	19.44M
Total Debt	5.82M	5.86M	4.97M	4.02M	4.44M
Total Liabilities	35.51M	36.66M	21.42M	9.77M	9.86M
Stockholders Equity	-24.91M	-7.80M	-2.57M	17.94M	16.34M
Cash Flow
Free Cash Flow	-26.47M	-19.15M	-16.85M	-21.83M	-18.41M
Operating Cash Flow	-25.89M	-18.06M	-15.28M	-20.85M	-16.46M
Investing Cash Flow	-573.85K	-1.08M	-1.57M	-973.56K	-1.65M
Financing Cash Flow	8.66M	28.98M	6.94M	22.86M	20.62M

VolitionRX Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Positive. The current price of 0.74 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.63, and above the 200-day MA of 0.61, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.82 is Neutral, neither overbought nor oversold. The STOCH value of 74.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VNRX.

VolitionRX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VNRX	54 Neutral	$76.43M	―	138.92%	―	64.15%	41.65%
ENZB	54 Neutral	$35.76M	―	-13.95%	―	―	―
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
BNR	51 Neutral	$88.67M	―	-37.15%	―	-0.26%	60.09%
BIAF	50 Neutral	$9.76M	―	-290.85%	―	78.40%	22.41%
BDSX	45 Neutral	$52.76M	―	-1454.41%	―	35.76%	47.48%
BNGO	41 Neutral	$11.87M	―	-127.82%	―	-24.04%	84.11%

VolitionRX Corporate Events

VolitionRX Stockholders Approve Key Proposals at Meeting

At the Annual Meeting on June 18, 2025, VolitionRX‘s stockholders voted on four proposals. The stockholders elected eight members to the Board of Directors, ratified the selection of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm, approved the compensation of the company’s named executive officers, and approved an amendment to the Restated Certificate.

The most recent analyst rating on (VNRX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.